Rasha Aboelhassan: How can we manage HCC patients with high-risk features?
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, posted on LinkedIn:
“How can we manage HCC patients with high-risk features?
Should we begin with two weapons, having two mechanisms of actions like in Atezolizumab- bevacizumab?
Or
Two strong immunotherapy like STRIDE regimen?
This is one of the most important debates in HCC MDT all over the world.
by the end of each debate , still high-risk features reflect bad prognosis.
Yesterday, we highlighted the importance of MDT, especially for patients with high-risk features. They usually have deteriorated liver function and need closure follow-up.
In our discussion, we used not only data coming from international clinical trials but also real-world data, which enrolled high-risk patients in comparison with lower risk HCC patients
Thanks for all participants in our MDT.”
Authors: Sang Youn Hwang, Hyun Young Woo, Jeong Heo, Hyung Jun Kim, Young Joo Park, Ki Youn Yi, Yu Rim Lee, Soo Young Park, Woo Jin Chung, Byoung Kuk Jang, Won Young Tak
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics. Rasha has been accepted as a member of staging and Prognostic Factors Group of lung cancer SPFG.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023